TPST Tempest Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1544227 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-12.6%
TTM EPS YoY67.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-1,797.6%
ROA-313.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets120.9%
Debt / equity—
Current ratio0.34x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.39x
Accruals ratio-189.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $207,000 | $1.82M | $114,000 | $539,000 | $570,000 | $3.87M | $7.63M | $10.74M |
| SG&A expense | $2.62M | $3.43M | $5.42M | $3.54M | $3.03M | $4.09M | $3.31M | $3.18M |
| Operating income | -$2.82M | -$5.25M | -$27.72M | -$4.08M | -$3.60M | -$7.97M | -$10.94M | -$13.92M |
| Interest expense | — | $0 | $0 | $0 | $0 | $46,000 | $161,000 | $247,000 |
| Income tax | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$3.63M | -$5.24M | -$27.70M | -$4.02M | -$3.51M | -$7.87M | -$10.86M | -$13.81M |
| EBITDA | -$2.77M | -$5.19M | -$27.66M | -$4.01M | -$3.53M | -$7.90M | -$10.87M | -$13.87M |
| EPS (basic) | -0.21 | -0.34 | -2.53 | — | -0.79 | -2.07 | -3.16 | — |
| EPS (diluted) | -0.21 | -0.34 | -2.53 | — | -0.79 | -2.07 | -3.16 | — |
| Weighted avg. shares (diluted) | 16.91M | 15.22M | 10.93M | — | 4.44M | 3.80M | 3.44M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $897,000 | $779,000 | $1.80M | $7.71M | $7.96M | $14.72M | $21.95M | $30.71M |
| Current assets | $1.61M | $1.70M | $2.45M | $8.27M | $8.10M | $15.10M | $22.43M | $31.47M |
| PP&E, net | $429,000 | $486,000 | $545,000 | $605,000 | $681,000 | $748,000 | $817,000 | $886,000 |
| Total assets | $8.76M | $9.63M | $10.75M | $16.93M | $17.13M | $24.48M | $32.16M | $41.49M |
| Current liabilities | $4.67M | $4.45M | $3.31M | $3.31M | $3.52M | $7.14M | $13.18M | $14.22M |
| Short-term debt | — | — | — | $0 | $0 | $0 | $4.19M | $6.35M |
| Long-term debt | — | — | — | — | — | — | $4.20M | $0 |
| Total debt | — | — | — | — | — | — | $8.39M | $6.35M |
| Total liabilities | $10.59M | $10.72M | $9.93M | $10.26M | $10.78M | $14.70M | $21.03M | $22.36M |
| Shareholders' equity | -$1.83M | -$1.09M | $822,000 | $6.67M | $6.35M | $9.78M | $11.13M | $19.13M |
| Net debt | — | — | — | — | — | — | -$13.56M | -$24.36M |
| Shares outstanding | 16.89M | 15.98M | 14.34M | 4.93M | 4.44M | 4.44M | 3.52M | 3.38M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.05M | -$2.78M | -$7.60M | -$3.57M | -$6.78M | -$8.43M | -$8.04M | -$10.15M |
| Capital expenditure | — | $0 | $0 | $0 | $0 | $0 | $0 | $3,000 |
| Free cash flow | — | -$2.78M | -$7.60M | -$3.57M | -$6.78M | -$8.43M | -$8.04M | -$10.15M |
| Investing cash flow | — | $0 | $0 | $0 | $0 | $0 | $0 | -$3,000 |
| Financing cash flow | $2.17M | $1.75M | $1.70M | $3.77M | $13,000 | $1.20M | -$721,000 | $17.95M |
| Depreciation & amortization | $57,000 | $59,000 | $60,000 | $65,000 | $66,000 | $67,000 | $68,000 | $49,000 |
| Stock-based compensation | -$54,000 | -$117,000 | $226,000 | $576,000 | $61,000 | $1.09M | $1.39M | $1.33M |
Free plan shows the latest 8 periods; Pro shows all 61 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.